Equillium, Inc.

Equillium, Inc. announced it has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia for its Phase 1 clinical trial of EQ504. The company expects to begin dosing healthy participants by early November 2026. The Phase 1 trial is a randomized, double-blinded, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EQ504. It includes single ascending dose, multiple ascending dose with GI biopsies, and food effect cohorts.

Equillium, Inc. reported a net loss of $(10.0) million for the six months ended June 30, 2026, an improvement from $(14.4) million in the prior year. The company significantly strengthened its financial position with cash and cash equivalents reaching $57.2 million, primarily due to a $35.0 million private placement in March 2026. Management expects current cash to fund operations into 2029, supporting the advancement of its clinical programs, including a planned Phase 1 study for EQ504 in Q4 2026.

Equillium reported a net loss of $4.7 million for the second quarter ended June 30, 2026, an improvement from a $5.7 million net loss in the same period of 2025. The company maintained a strong financial position with $57.2 million in cash and cash equivalents, projected to fund operations into 2029. Equillium also highlighted significant clinical progress, including the anticipated initiation of a Phase 1 study for EQ504 in Q4 2026 and the start of IND-enabling development for EQ504 as an inhaled therapy and EQ302 for celiac disease.

Equillium, Inc. announced that its Compensation Committee granted an inducement award of nonstatutory stock options to a new employee on June 1, 2026. The award covers 145,000 shares of common stock at an exercise price of $3.08 per share. These options will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months, subject to continued service.

Equillium, Inc. held its 2026 Annual Meeting of Stockholders, where key proposals were approved. Stockholders voted to approve an amendment to the company's certificate of incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20, at the Board's discretion. Additionally, the authorized number of common stock shares was increased from 200,000,000 to 400,000,000. Charles McDermott and Bruce Steel were elected as Class II directors, and the Board size was reduced to six members. The appointment of Crowe LLP as the independent registered public accounting firm for 2026 was also ratified.

Equillium, Inc. announced that its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The presentation is scheduled for Wednesday, June 3, 2026, at 4:55pm EDT. Management will also be available to meet with registered investors attending the conference.

Equillium, Inc. announced it will host a virtual investor event on May 27, 2026, at 11:00 AM ET. The event will feature new preclinical data presented by Chief Scientific Officer Stephen Connelly, Ph.D., focusing on AhR modulators and the relationship between AhR activation and miR-124 induction. These findings aim to provide a unifying mechanistic framework for the paradoxical relationship between AhR and miR-124, which has implications for developing therapies targeting this axis in inflammatory diseases. The webinar will also include a live question-and-answer session with management.

Equillium reported a net loss of $5.3 million for Q1 2026, an improvement from $8.7 million in Q1 2025. The company significantly boosted its liquidity, with cash and cash equivalents rising to $61.3 million as of March 31, 2026, up from $30.3 million at year-end 2025, primarily due to a $35.0 million private placement. Management projects this capital will fund operations into 2029, supporting the advancement of EQ504 into a Phase 1 study by mid-2026.

Equillium reported a reduced net loss of $(5.3) million for the first quarter ended March 31, 2026, compared to $(8.7) million in the same period last year, with R&D and G&A expenses decreasing. The company's cash and cash equivalents significantly increased to $61.3 million, extending its operational runway into 2029, partly due to a $35 million private placement. Additionally, Equillium appointed Snehal Naik, Ph.D., as Chief Development Officer and confirmed that its Phase 1 study for EQ504 is on track for mid-2026 initiation.

Equillium reported a reduced net loss of $5.3 million for Q1 2026, down from $8.7 million in Q1 2025, driven by lower R&D and G&A expenses. The company also announced the appointment of Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical strategy. Equillium is on track to initiate a Phase 1 study for EQ504 in mid-2026, with data expected six months later, and its cash and cash equivalents of $61.3 million are expected to fund operations into 2029.